CMC Sections of Regulatory Filings and CMC Regulatory Compliance during Investigational and Postapproval Stages
Introduction ... 200 Pharmaceutical Quality ... 200Drug Substance ... 201 Manufacture ... 202 Characterization (Structure Elucidation)... 204 Control of Drug Substance (Specifications) ... 205 Reference Standards or Materials ... 206 Container Closure System ... 206 Stability ... 207 Drug Product .....
Gespeichert in:
Format: | Buchkapitel |
---|---|
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction ... 200
Pharmaceutical Quality ... 200Drug Substance ... 201
Manufacture ... 202
Characterization (Structure Elucidation)... 204
Control of Drug Substance (Specifications) ... 205
Reference Standards or Materials ... 206
Container Closure System ... 206
Stability ... 207
Drug Product ... 207Description and Composition of the Drug Product ... 207
Pharmaceutical Development ... 207
Components of the Drug Product ... 208
Drug Product Development ... 208Manufacture (Manufacturer(s)/Method of Manufacture) ...210
Control of Excipients (Specifications) ...211
Control of Drug Product (Specifications) ...211
Justification of Specification(s) ...214
Reference Standards or Materials ...214
Container Closure System ...214
Stability ... 215The chemistry, manufacturing, and controls (CMC) section of a regulatory filing
[investigational new drug (IND), IND amendments, IND annual reports, new
drug application (NDA) or biologics license application (BLA), postapproval
CMC supplements, and NDA annual reports] contains detailed information pertaining to the characteristics, manufacturing, and quality aspects of the drug substance and drug product. Under the International Conference on Harmonization
(ICH) Common Technical Document (CTD) format,1 the CMC section is referred
to as the quality section and the structure is outlined in the ICH CTD guidance.2
This chapter first discusses the details of the quality section of a CTD, followed
by how CMC changes are managed during the IND development phases and
postapproval stages. As this book addresses the Food and Drug Administration
(FDA) regulatory affairs, the focus of the discussions is primarily based on the
US FDA expectations and requirements. Other health authority requirements
such as those found in Europe, Canada, Japan, or China could vary significantly
from this chapter with respect to CMC, and the reader is encouraged to seek other
reference materials as appropriate. |
---|---|
DOI: | 10.1201/b16471-12 |